Committee Composition

  Audit Nominating and Governance Compensation
Scott A. Canute
Scott A. Canute
Magis Consulting LLC

Scott A. Canute joined the Flexion Board of Directors in 2015. Scott spent 25 years at Eli Lilly and Company, ultimately serving as President, Global Manufacturing Operations from 2004 until 2007. In this capacity, Scott directed all manufacturing and supply chain activities for Lilly’s global operations. Following his distinguished career at Lilly, Scott served as President of Global Manufacturing and Corporate Operations at Genzyme from 2010 until 2011. In this role, Scott served as the architect and leader of the organizational evolution that resulted in the supply of life-saving products to patients in need. Scott currently serves as a member of the Board of Oncobiologics, Inc and the Technology Advisory Board of Moderna Therapeutics. Scott previously served as board member of Allocure Inc, Inspiration Biopharmaceuticals, the National Association of Manufacturers and the Indiana Manufacturers Association. Scott received his Bachelor of Science degree from the University of Michigan and a Master of Business Administration from Harvard Business School.

  Member of the Nominating and Governance Committee  
Sam Colella MBA
Image of Sam Colella MBA
Sam Colella MBA
Versant Ventures

Mr. Colella co-founded Versant Ventures with six other Managing Directors in 1999. He has more than 20 years of operating experience in the high-technology industry and more than 25 years of investing experience in the healthcare sector. Prior to founding Versant, Mr. Colella managed one of the first life sciences-focused investing groups as a general partner with Institutional Venture Partners (IVP). Previously, he was President of a New York Stock Exchange company and held a variety of positions across a broad array of diverse businesses, including President of Spectra-Physics and Senior Manager of the Technical Products Division of Corning Glass. Having managed investments in medical devices, biotechnology, and health care technology companies, Mr. Colella is credited with an extensive list of successful public life sciences companies, including Alexza Pharmaceuticals, Argonaut Technologies, Arthrocare, Athena Neurosciences, Aviron, CV Therapeutics, Endosonics, Genomic Health, IVAC Holdings, Onyx Pharmaceuticals, Pharmacopeia, Symyx Technologies, Thermage, Tularik, and Vivus. He is currently a Director of Alexza Pharmaceuticals, EuroVentures, Genomic Health, Jazz Pharmaceuticals, Rennovia, and Veracyte, and he serves as Chairman of the Board for Fluidigm.

  Chair of the Nominating and Governance Committee Member of the Compensation Committee
Heath Lukatch PhD
Image of Heath Lukatch PhD
Heath Lukatch PhD
Novo Ventures (US)

Heath Lukatch joined Novo Ventures (US) Inc. in San Francisco, California in 2006. He is chairman of the board of directors of Inogen Inc. and NeuroTherapeutics Pharma Inc., and a member of the board of directors of AnaptysBio Inc., Cianna Medical Inc., FLAPCo LLC. and Panmira Pharmaceuticals LLC., and was a board member of Amira Pharmaceuticals, Elevation Pharmaceuticals Inc., FoldRx Pharmaceuticals Inc., InSound Medical Inc. and Synosia Therapeutics. Prior to joining Novo Ventures (US) Inc., Heath was a Managing Director for Piper Jaffray Ventures and SightLine Partners, and a bench scientist at Cetus, Chiron and Roche Bioscience. While at Piper Jaffray and Sightline he was responsible for biotech venture investments and served on the boards of several biotech and medical device companies. Previously, he was at McKinsey & Co. where his primary focus was on strategy consulting for biopharmaceutical companies. Heath also brings entrepreneurial experience from his role as founder and CEO of AutoMate Scientific Inc. a biotechnology instrumentation company. Heath holds a PhD in neuroscience from Stanford University and a BA in biochemistry from the University of California at Berkley.

    Member of the Compensation Committee
Patrick Mahaffy MA
Image of Patrick Mahaffy MA
Patrick Mahaffy MA
Clovis Oncology

Patrick J. Mahaffy is the co-founder, CEO & President of Clovis Oncology. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the boards of directors of Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Flexion Therapeutics, Inc. He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University.

  Member of the Nominating and Governance Committee Chair of the Compensation Committee
Sandy Mahatme LLM
Sandy Mahatme LLM
Sarepta Therapeutics

Mr. Mahatme became Sarepta's Senior Vice President and Chief Financial Officer in November 2012. He is currently responsible for the finance, investor relations, facilities, IT and corporate communications functions at Sarepta, which is a rapidly growing, late-stage biotechnology company with a focus on neuromuscular and infectious disease therapeutic areas. From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, and focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing and global manufacturing expansion. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc. for over eight years in senior roles in Business Development and Corporate Tax. Mr. Mahatme started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Laws (LL.M.) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association.

Chair of the Audit Committee    
Ann Merrifield MBA
Ann Merrifield MBA
Independent, Former CEO of PathoGenetix

Ms. Merrifield has spent much of her career leading the development of high growth, profitable biotechnology businesses. She most recently served as President and CEO of Pathogenetix Inc. During an 18-year tenure at Genzyme Corporation, a diversified, global biotechnology company, Ms. Merrifield served as President of Genzyme Biosurgery, where she led global business strategy across a complex portfolio of biologics, therapeutic devices and combination products; and as Vice President of Marketing, General Manager and then President of Genzyme Genetics, where she played an instrumental role in developing and shaping its diagnostic business. Prior to Genzyme, Ms. Merrifield was a Partner at Bain and Company, a global strategy consulting firm, and an Investment Officer at Aetna Life & Casualty. She serves as Trustee and Director on several boards including Partners Continuing Care, the non-acute care services division of Partners HealthCare; the YMCA of Greater Boston; and MassMutual Premier, Select and MML Series Investment Funds. Ms. Merrifield earned a Bachelor of Arts in Zoology and a Master of Education from The University of Maine, and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.

 

Member of the Audit Committee    
Alan W. Milinazzo
Image of Alan W. Milinazzo
Alan W. Milinazzo
President and CEO, InspireMD

Mr. Milinazzo brings more than two and a half decades of executive management experience in the life sciences sector and is currently the CEO of InspireMD. He spent 12 years as an executive with Boston Scientific Corporation in numerous executive roles, including Vice President of Marketing for SCIMED Europe. Mr. Milinazzo then served as Vice President of Medtronic Inc.’s Vascular business, as well as, Vice President and General Manager of Medtronic’s Coronary and Peripheral businesses. He was instrumental in the development and commercialization of a number of key products while at Medtronic, including the company’s first drug coated stent platform, Endeavor, which has generated over $1 billion in revenues since its launch. Most recently, Mr. Milinazzo served at Orthofix International in 2005 as Chief Operating Officer and succeeded to the position of Chief Executive Officer in April of 2006.

Mr. Milinazzo currently serves as a director of Flexion Therapeutics, Medpace and Trimedics and holds a bachelor’s degree, Cum Laude, from Boston College.

    Member of the Compensation Committee
Mark Stejbach
Mark Stejbach
Alkermes

Mark Stejbach joined the Flexion Board of Directors in 2016. He currently serves as Senior Vice President and Chief Commercial Officer at Alkermes and has 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care and finance. Prior to his current role, Mark served as the Chief Commercial Officer at Tengion, Inc. from 2008-2012 and previously held senior positions at Merck and Biogen. Mark received his MBA from the Wharton School, University of Pennsylvania and a Bachelor of Science in mathematics from Virginia Tech.

Member of the Audit Committee    
= Chair of the Board = Chair = Member